Clinical trial
A Multicentre, Double-blind, Randomised, Placebo - Controlled Phase II Study to Assess Efficacy, Safety and Pharmacokinetics of Inhaled Esketamine in Subject With Treatment-resistant Depression in the Course of Major Depressive Disorder
NCT03965858 is registered in ClinicalTrials.gov with Celon Pharma SA as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Multicentre, Double-blind, Randomised, Placebo - Controlled Phase II Study to Assess Efficacy, Safety and Pharmacokinetics of Inhaled Esketamine in Subject With Treatment-resistant Depression in the Course of Major Depressive Disorder
- Lead sponsor
- Celon Pharma SA
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- February 25, 2019
- Completion date
- April 24, 2020
- Enrollment
- 88 (actual)
- Sites
- 12
Conditions
As the registry lists them; a condition with its own page is linked.